Application of beta-adrenoblockers in patients with glaucoma, possibilities of predicting and minimizing risk of side effects
https://doi.org/10.34215/1609-1175-2021-3-17-23
Abstract
The review of the literature on general issues concerning systematic and local (ophthalmological) beta-blockers (BB). Therapeutic effects, aspects of selectivity and the advantages of modern cardiotropic agents are highlighted. Special attention is paid to the frequency of side effects when taking systematic and ophthalmological BB and measures to decrease the frequency. Systematic additive effects in case of glaucoma caused by a range of chronic diseases were pointed out on the basis of its clinical experience. Recommendations to minimize the risk of BB side effects among patients having glaucoma and accompanying diseases of cardiovascular and respiratory systems were proposed.
About the Authors
E. E. Filimonova
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch
Russian Federation
Russian Federation
MD,
211 Tikhookeanskaya St., Khabarovsk, 680033
E. L. Sorokin
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch;
Far Eastern State Medical University
Russian Federation
Russian Federation
MD., PhD, deputy head for scientific work, 211 Tikhookeanskaya St., Khabarovsk, 680033;
professor of the Department of General and Clinical Surgery, 35 Muravyeva-Amurskogo St., Khabarovsk, 680000
M. A. Esina
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch
Russian Federation
Russian Federation
MD,
211 Tikhookeanskaya St., Khabarovsk, 680033
L. V. Pavlyushchenko
S. Fyodorov “Eye Microsurgery” Federal State Institution, Khabarovsk Branch
Russian Federation
Russian Federation
MD,
211 Tikhookeanskaya St., Khabarovsk, 680033
References
1. Shayduk OYu, Taratukhin EO. Sympathetic activity and arterial hypertension: Potential for correction. Russian Journal of Cardiology. 2013;(2):61−4 (In Russ).
2. Martsevich SYu, Tolpygina SN. Beta-adrenoblokatory. Kardiologiya: Natsionalnoye Rukovodstvo. Moscow: GEOTAR-Media; 2007:377−95 (In Russ).
3. Erichev VP, Petrov SYu, Volzhanin AV, Safonova DM, Yaremenko TV, Kazaryan SA. Alpha-adrenergic receptor agonists in terms of modern views on glaucoma monitoring and treatment. Russian Journal of Clinical Ophthalmology. 2019;19(2):87−91 (In Russ).
4. Leinck JR. In introduction to cardiovascular physiology. London: Butterworth; 1991.
5. Nebieridze DV. Topical issues of beta-blockers use in various clinical situations. Medical Council. 2018;(12):12−7 (In Russ).
6. The task force on beta-blockers of Eropean Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart. 2004;25:1341−62.
7. Podzolkov VI, Osadchiy KK. Beta-adrenoblokatory: vzglyad XXI veka. Russian Medical Journal. 2006;10:737−42 (In Russ).
8. Makolkin VI. Stable coronary heart disease treatment: focus on beta-adrenoblockers. Cardiovascular Therapy and Prevention. 2008;7(6):89−93 (In Russ).
9. Ukholkina GB. Beta-blokatory – sovremennoye sostoyaniye voprosa. Russian Medical Journal. 2010;18(22):1360−65 (In Russ).
10. Makolkin VI. Znacheniye beta-adrenoblokatorov v lechenii arterial›noy gipertonii. Vrach. 2007;1:70−4 (In Russ).
11. Radchenko AD. Mesto beta-blokatorov v lechenii arterial’noy gipertenzii v 2017 g: Tak li vse plokho? Arterialnaya Gipertenziya. 2017;2:9−54 (In Russ).
12. Karpov YuA, Shubina AT. Beta-blokatory v lechenii profilaktike ishemicheskoy bolezni serdtsa. Serdtse. 2005;4(1):32−5 (In Russ).
13. Martsevich SYu. Beta-adrenoblockers: Treatment principles in international clinical guidelines. Cardiovascular Therapy and Prevention. 2005;4(4):4−9 (In Russ).
14. Aleksandrov AA, Shatskaya OА, Kuharenko SS, Drozdova EN, Bondarenko IZ, Tabidze ND, Shestakova MV. Heart failure, diabetes, beta-blockers and risk of hypoglycemia. Rational Pharmacotherapy in Cardiology. 2008;4(3):47−51 (In Russ).
15. Avdeev SN, Baymakanova GE. Strategiya vedeniya kardiologicheskogo patsiyenta, stradayushchego KHOBL. Kardio-pulmonologicheskiye vzaimootnosheniya. Serdtse. 2008;4(3):47−51 (In Russ).
16. Lysenko OI, Malyshev AV. Results of a definition of depressive status in patients with glaucoma treated with beta-blockers or travoprost. Russian Journal of Clinical Ophthalmology. 2012;13(4):130−1 (In Russ).
17. Martsevich SY, Kutishenko NP, Shilova EV, Deev AD, Shalnova SA, Oganov RG, et al. Сomparison of therapies based on carvedilol and metoprolol in hypertensive patients with overweight or obesity. The first results of camellia trial. Rational Pharmacotherapy in Cardiology. 2009;5(1):23−7 (In Russ).
18. Shekhyan GG, Yalymov AA, Shchikota AM, Zadionchenko VS, Terpigorev SA, Kabanova TG. Comparative efficacy and safety of metoprolol formulations in the treatment of cardiovascular diseases. Russian Medical Journal. 2016;24(19):1271−5 (In Russ).
19. Nebieridze DV. Beta-blockers: Urgent aspcts. Arterial Hypertension. 2009;15(17):413–5 (In Russ).
20. Melekhov AV, Ryazantseva EE. Beta-blockers and bronchial obstruction: New approach. Lechebnoye Delo. 2012;3:21−8 (In Russ).
21. Lupanova VP. Kardioselektivnyy β-blokator bisoprolol v lechenii bolnykh s serdechno-sosudistymi zabolevaniyami. Russian Medical Journal. 2012;3:86 (In Russ).
22. Kukes VG. Metabolizm lekarstvennykh sredstv: Kliniko-farmakologicheskiye aspekty. Moscow: Reafarm; 2004 (In Russ).
23. Lukina YuV, Martsevich SYu. The bisoprolol – a high selective beta-blocker according to evidence based medicine. Rational Pharmacotherapy in Cardiology. 2010;6(1):103−7 (In Russ).
24. Smirnova MD, Ageev FT. An algorithm for selection of antihypertensive therapy, a place of long-acting beta-blockers. Russian Medical Journal. 2018;26(11–1):42–6 (In Russ).
25. Kiselyova OA, Yakubova LV, Bessmertny AM. Beta-blockers in glaucoma therapy: History and perspectives. Effektivnaya Farmakoterapiya. 2018;22:14−8 (In Russ).
26. Balalin SV, Fokin VP. Pharmacotherapy for POAG. Individual approach. Russian Journal of Clinical Ophthalmology. 2019;19(1):43–8 (In Russ).
27. Kukes VG, Sychev DA, Andreev DA. Clinical pharmacology of beta-blockers. Russian Medical Journal. 2005;14:932 (In Russ).
28. Kuroyedov AV, Ogorodnikova VYu. Beta-blockers in primary openangle glaucoma therapy: advantages and limitations. Review. Ophthalmology in Russia. 2008;5(4):4−18 (In Russ).
29. Egorov EA, Egorov AE. Beta-blockers in treatment of glaucoma. Back to the future. Literature review. Russian Journal of Clinical Ophthalmology. 2013;13(3):92−5 (In Russ).
30. Makogon SI, Onishchenko AL, Yatsenko LL, Karmanova OA. The efficacy of first-choice therapy in the treatment of newly diagnosed primary glaucoma. National Journal Glaucoma. 2018;17(2):28−37 (In Russ).
31. Kuroyedov AV. Prospects of combined antiglaucoma drugs usage (literary review). Russian Journal of Clinical Ophthalmology. 2007;8(4):176 (In Russ).
32. Babushkin AE, Orenburkina OI, Matyukhina EN. The efficacy of maximum hypotensive therapy with fixed dose combinations in primary open-angle. Russian Journal of Clinical Ophthalmology. 2016;16(4):181−4 (In Russ).
33. Kurysheva NI. Betaksolol v lechenii pervichnoy glaukomy. Glaukoma. 2006;2:73−6 (In Russ).
34. Egorov EA, Egorov AE, Eliseeva TO, Egorova TE. Undesirable effects of hypotensive treatment of glaucoma. Literary review. Russian Journal of Clinical Ophthalmology. 2011;12(3):111−3 (In Russ).
35. Sherstneva LV, Podgornaya NN. Sistemnyye pobochnyye effekty protivoglaukomnykh preparatov i ikh znacheniye v geriartricheskoy praktike. Klinicheskaya Gerontologiya. 2006;7:33−4 (In Russ).
36. Egorov AE, Glazko NG, Movsisyan AB. IOP-lowering and neuroprotective treatment for glaucoma: Reality and prospects. Russian Journal of Clinical Ophthalmology. 2019;19(3):128−37 (In Russ).
37. Kiseleva OA, Kosakyan SM, Yakubova LV, Vasilenkova LV. Interaction of antiglaucomatous drugs in patients with chronic concomitant diseases. Russian Journal of Clinical Ophthalmology. 2016;16(1):16−9 (In Russ).
38. Kiseleva OA, Yakubova LV, Bessmertny AM. Beta-blockers in modern glaucoma therapy: Review. Ophthalmology in Russia. 2013;10(2):20−3 (In Russ).
39. Erichev VP, Vitkov AA. Topical beta-blockers: Interactions and adverse events (analytical review). XVIII Vserossiyskaya shkola oftalmologa: sb. nauch. trudov. 2019:37−45 (In Russ).
40. Filimonova EE, Kogan MP, Esina MA. Chastota i struktura soputstvuyushchey somaticheskoy patologii, osobennosti yeyo lecheniya u patsiyentov s pervichnoy otkrytougolnoy glaukomoy. Modern Technologies in Ophthalmology. 2017;2:140−2 (In Russ).
41. Hoste AM. Beta-blockers in glaucoma. Medical diagnosis & therapy. Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, eds. Glaucoma, 2nd Edition. London: Elsevier; 2014:548–58.
42. Miroshnichenko II, Ptitsina SN. Geneticheskiy polimorfizm i farmakokinetika lekarstvennykh sredstv. Klinicheskaya Farmakokinetika. 2005;2:35−9 (In Russ).
43. Agafonova TYu, Sobyanin NA, Gavrilova TV. Progression of primary open-angle glaucoma n type 2 diabetes: comorbidity issue. Russian Journal of Clinical Ophthalmology. 2017;17(1):22−5 (In Russ).
44. Kislyak OA, Leont›eva MS. Patsient s arterial›noy gipertenziey i assotsiirovannymi klinicheskimi sostoyaniyami: Voprosy lecheniya. Systemic Hypertension. 2012;9(3):14−7 (In Russ).
45. Egorov EA, Astakhov YuS, Shchuko AG. Natsionalnoe rukovodstvo po glaukome dlya poliklinicheskikh vrachey. Moscow: Capital Business; 2008 (In Russ).
46. Onishchenko AL, Kolbasko AV, Zakharova AV, Onishchenko EG, Zhilina NM. Ocular hypotensive effect of systemic beta-blockers in patients with primary glaucoma and arterial hypertension. The Russian Annals of Ophthalmology. 2017;133(2):46−51 (In Russ).
47. Sychjov DA, Moshetova LK. Clinical and pharmacological aspects of combined pathology: cardiovascular diseases and glaucoma. National Journal Glaucoma. 2014;13(2):99−104 (In Russ).
48. Filimonova EE, Sorokin EL, Kogan MP, Pashentsev YE. Development of additive systemic effects when taking β-blockers in patients with glaucoma and concurrent chronic diseases. The Russian Annals of Ophthalmology. 2020;136(6–2):155−64 (In Russ).
49. Filimonova EE, Sorokin EL, Kogan MP, Esina MA. Comparative analysis of frequency and severity of negative adverse reactions in various variants of using betablockers in patients with combination of primary open-angle glaucoma and cardiovascular disease. Modern Technologies in Ophthalmology. 2019;(2):186−90 (In Russ).
50. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2014;1:7−94 (In Russ).
Review
For citations:
Filimonova E.E., Sorokin E.L., Esina M.A., Pavlyushchenko L.V. Application of beta-adrenoblockers in patients with glaucoma, possibilities of predicting and minimizing risk of side effects. Pacific Medical Journal. 2021;(3):17-23. (In Russ.) https://doi.org/10.34215/1609-1175-2021-3-17-23
Views:
307
Email this article 